| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/28/2002 | WO2002024613A2 Resorcinol derivatives |
| 03/28/2002 | WO2002024610A2 Method for producing an antineoplastic |
| 03/28/2002 | WO2002024609A2 Method for producing a radioprotector |
| 03/28/2002 | WO2002024273A1 Tumor treatment |
| 03/28/2002 | WO2002024239A1 Method and hemostatic patch for effecting local hemostasis |
| 03/28/2002 | WO2002024230A1 Solid preparations |
| 03/28/2002 | WO2002024227A1 Tumor cell proliferation inhibitors |
| 03/28/2002 | WO2002024226A2 Photosensitisers |
| 03/28/2002 | WO2002024223A2 Prevention and treatment of streptococcal and staphylococcal infection |
| 03/28/2002 | WO2002024217A1 Use of il-8 protein modulators in the treatment of viral infections |
| 03/28/2002 | WO2002024216A2 Method for use of igf-binding protein for selective sensitization of target cells in vivo |
| 03/28/2002 | WO2002024209A1 Fluid for haemofiltration |
| 03/28/2002 | WO2002024208A1 Compositions comprising lignin and methods of making and using the same |
| 03/28/2002 | WO2002024207A1 Diuretic or sulphonylurea for use in antiviral treatment |
| 03/28/2002 | WO2002024206A1 Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
| 03/28/2002 | WO2002024205A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE BY THE ADMINISTRATION OF Δ5-ANDROSTENE-3β-OL-7,17 DIONE AND METABOLIZABLE PRECURSORS THEREOF |
| 03/28/2002 | WO2002024204A2 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 03/28/2002 | WO2002024203A2 Controlled release formulations for oral administration |
| 03/28/2002 | WO2002024202A1 Nasal delivery of apomorphine in combination with glycol derivatives |
| 03/28/2002 | WO2002024201A1 Method of treating aquatic animals with an antimicrobial agent and chelating agent |
| 03/28/2002 | WO2002024200A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 03/28/2002 | WO2002024198A1 Novel therapy |
| 03/28/2002 | WO2002024197A1 Fatty acid synthase inhibitors |
| 03/28/2002 | WO2002024196A1 Iron compositions |
| 03/28/2002 | WO2002024195A1 Method of treating gastrointestinal disorders, particularly colitis |
| 03/28/2002 | WO2002024194A2 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 03/28/2002 | WO2002024193A1 Stabilised fibrate microparticles |
| 03/28/2002 | WO2002024191A1 Therapeutic and prophylactic drugs of myopia |
| 03/28/2002 | WO2002024190A1 Use of r-arylpropionic acids for producing medicaments for treating illnesses with a rheumatic nature |
| 03/28/2002 | WO2002024189A1 Cell activator |
| 03/28/2002 | WO2002024188A1 Use inos inhibitors to treat or prevent myopia |
| 03/28/2002 | WO2002024187A2 Treatment of diseases with adamantane derivatives |
| 03/28/2002 | WO2002024186A1 1-amino-alkylcyclohexanes as trypanocidal agents |
| 03/28/2002 | WO2002024185A2 Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 03/28/2002 | WO2002024184A2 Mechanically stable dosage forms containing ubiquinones |
| 03/28/2002 | WO2002024183A1 Use of myxoxanthophyll and/or echinenone for the prophylactic and/or therapeutic treatment of undesirable physical conditions conditioned or favoured by oxidative processes |
| 03/28/2002 | WO2002024182A1 Ectoparasite formulation |
| 03/28/2002 | WO2002024181A2 The use of melatonin for induction of general anesthesia |
| 03/28/2002 | WO2002024180A2 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 03/28/2002 | WO2002024179A2 Method for reducing toxicity of combined chemotherapies |
| 03/28/2002 | WO2002024178A2 Method for reducing toxicity of combined chemotherapies |
| 03/28/2002 | WO2002024177A2 Methods of identifying inhibitory compounds and uses thereof |
| 03/28/2002 | WO2002024176A2 Treatment of tinnitus |
| 03/28/2002 | WO2002024174A2 Sustained release composition containing clarithromycin |
| 03/28/2002 | WO2002024172A1 Pharmaceutical semi-solid composition of isotretinoin |
| 03/28/2002 | WO2002024169A1 Spray drying process and compositions of fenofibrate |
| 03/28/2002 | WO2002024166A1 Oral preparations with favorable disintegration characteristics |
| 03/28/2002 | WO2002024163A1 Solid dose nanoparticulate compositions |
| 03/28/2002 | WO2002024162A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | WO2002024161A1 Suppositories sustained in the lower rectum |
| 03/28/2002 | WO2002024160A2 Long acting antidepressant microparticles |
| 03/28/2002 | WO2002024158A2 Pulmonary delivery in treating disorders of the central nervous system |
| 03/28/2002 | WO2002024154A2 Method for topical treatment of anthralin-responsive dermatological disorders |
| 03/28/2002 | WO2002024148A2 Method or treatment of tumors using transforming growth factor-alpha |
| 03/28/2002 | WO2002024146A2 Methods of decreasing or preventing pain using spicamycin derivatives |
| 03/28/2002 | WO2002024144A2 Use of transcription factors for treating inflammation and other diseases |
| 03/28/2002 | WO2002024100A1 Concurrent tooth repositioning and substance delivery |
| 03/28/2002 | WO2002024059A1 Methods for treating various eye disorders |
| 03/28/2002 | WO2002024002A2 Food supplement |
| 03/28/2002 | WO2002023995A1 Method of blocking free radical processes which result in media ted pathology without deleterious pro-oxidant side reactions |
| 03/28/2002 | WO2002023990A1 Disinfectant |
| 03/28/2002 | WO2002011743A3 Treatment of prostate cancer |
| 03/28/2002 | WO2002009651A3 Fatty acid synthase inhibitors |
| 03/28/2002 | WO2002005793A8 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 03/28/2002 | WO2002002595A9 Amphipathic linear peptides and compositions containing same |
| 03/28/2002 | WO2002002056A3 Method of treatment of seborrheic dermatitis |
| 03/28/2002 | WO2002000679A3 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group |
| 03/28/2002 | WO2001098236A3 7-phenyl-substituted tetracycline compounds |
| 03/28/2002 | WO2001097751A3 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 03/28/2002 | WO2001096336A3 6,5-fused bicyclic heterocycles |
| 03/28/2002 | WO2001091785A3 Use of hyaluronidase for preventing and treating cardio vascular diseases |
| 03/28/2002 | WO2001090106A3 Tryasolyl tropane derivatives as ccr5 modulators |
| 03/28/2002 | WO2001089493A3 Compositions containing a benzamide disulfide derivative for treating allergic diseases |
| 03/28/2002 | WO2001089479A3 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 03/28/2002 | WO2001087281A3 Method for enhancing cognitive function |
| 03/28/2002 | WO2001087236B1 Topical administration of pharmacological compositions for non-systemic treatment of pruritus |
| 03/28/2002 | WO2001087228A3 Sustained release pharmaceutical composition containing glipizide and method for producing same |
| 03/28/2002 | WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents |
| 03/28/2002 | WO2001085182A3 Combined cartilage and plant extract compositions |
| 03/28/2002 | WO2001085169A3 R-eliprodil for treating glaucoma |
| 03/28/2002 | WO2001085152A3 R-eliprodil for treating glaucoma |
| 03/28/2002 | WO2001083522A3 Growth factor modified protein matrices for tissue engineering |
| 03/28/2002 | WO2001083434A3 P-(sulfonyl)-aryl and heteroaryls amines |
| 03/28/2002 | WO2001080844A3 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| 03/28/2002 | WO2001080822A3 Effervescent granules and methods for their preparation |
| 03/28/2002 | WO2001078706A3 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| 03/28/2002 | WO2001076590A3 Treatment for benign positional vertigo using antiepileptics |
| 03/28/2002 | WO2001076585A3 Use of thiamphenicol for the treatment of chlamydia pneumoniae infections |
| 03/28/2002 | WO2001076575A3 The treatment of respiratory diseases |
| 03/28/2002 | WO2001076571A3 Use of sabcomeline in the treatment of anxiety |
| 03/28/2002 | WO2001076370A3 Anthelmintic combinations |
| 03/28/2002 | WO2001074859A3 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 03/28/2002 | WO2001072287A3 Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression |
| 03/28/2002 | WO2001072279A3 Medical emulsion for lubrication and delivery of drugs |
| 03/28/2002 | WO2001066560A3 Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders |
| 03/28/2002 | WO2001066144A3 Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity |
| 03/28/2002 | WO2001066107A3 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 03/28/2002 | WO2001064676A3 INHIBITORS OF p38-α KINASE |
| 03/28/2002 | WO2001064217A3 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| 03/28/2002 | WO2001064204A3 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents |